Getinge has announced commercial availability of the iCast covered stent system in the USA for the treatment of iliac arterial occlusive disease. In March 2023, the iCast covered stent received premarket approval from the US Food and Drug Administration (FDA) for the treatment of iliac arterial occlusive disease.
“We are very pleased that the iCast covered stent is now available to clinicians and hospital systems throughout the US for the treatment of this serious and often painful condition for patients,” said Patricia Fitch, president Getinge, North America. “This indication is another reflection of Getinge’s commitment to bringing our US customers the high-quality products and support they need for their patients.”
To support the commercial availability of the iCast covered stent, Getinge will take part in two upcoming medical meetings:
• Getinge will attend VIVA 2023 (30 October–2 November, Las Vegas, USA). Attendees will be able to access information about the iCast covered stent at the Getinge booth (#316) during the conference. Getinge will also sponsor a breakout session led by Christopher J Smolock, vascular surgeon at Mount Sinai Queens (New York, USA), titled “Effective treatment of TASC D common iliac lesions utilising the iCast covered stent system” during the meeting. Smolock’s presentation will be held Wednesday 1 November from 10:20am–10:45am PST in the Red Theater (Lafite Ballroom).
• Getinge will also attend the VEITHsymposium 2023 (14–18 November, New York, USA). Attendees can access information about the iCast covered stent at the Getinge booth (#513) and also attend a satellite symposium on Thursday 16 November from 4:00pm to 6:00pm EST.
“iCast, marketed outside the USA as Advanta V12, has been used by clinicians for more than 20 years. The use of iCast for the treatment of iliac arterial occlusive disease builds on this strong history of clinical experience and reflects Getinge’s commitment to developing and delivering products that represent the highest standards in safety and performance,” said Therese Mueller, vice president of sales, acute care therapies at Getinge. “We are very pleased that the system and the full range of Getinge support materials and services will now be available to support physicians who treat patients affected by this devastating disease.”
